TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05766163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DaVinci RARP
Description: Assisted-robotic radical prostatectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hugo RARP
Description: Assisted-robotic radical prostatectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versius RARP
Description: Assisted-robotic radical prostatectomy.
Study: NCT05513521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-velocity interval training
Description: For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
Study: NCT06668220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
Study: NCT05122676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
Description: This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains.
Study: NCT05280704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with lidocaine
Description: Volar digital block with lidocaine
Study: NCT06675201

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Description: Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
Description: Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.
Study: NCT06675578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tulsi gel
Description: After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gel
Description: After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
Study: NCT06675188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07275315
Description: PF-07275315 solution for injection (single use only)
Study: NCT05280704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with lidocaine
Description: Volar digital block with lidocaine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with saline
Description: Volar digital block with saline

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volar digital block with saline
Description: Volar digital block with saline
Study: NCT03570879

Intervention type: DEVICE
Intervention: Power morcellation
Description: Power morcellation of surgical specimens after laparoscopic myomectomy.

Intervention type: PROCEDURE
Intervention: Transvaginal extraction
Description: Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
Study: NCT06256757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fenestration
Description: Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fenestration
Description: Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
Study: NCT04628663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration
Study: NCT04793633

Intervention type: COMBINATION_PRODUCT
Intervention: LINFU™ Technique
Description: Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
Study: NCT05685472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
Study: NCT05284552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Injectable Solution
Description: Subcutaneous injection
Study: NCT06675188

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection (single use only)
Study: NCT06675617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allay Aortic Stent
Description: Endovascular treatment of an aortic dissection
Study: NCT06526520

Intervention type: DRUG
Intervention: Exposure to progesterone or HRT medication
Description: to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol

Intervention type: DRUG
Intervention: Exposure to progesterone or HRT medication
Description: to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Study: NCT06678854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training about Aphasia
Description: Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
Study: NCT04931095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be orally ingested via a brownie

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol will be orally ingested via a flavored drink
Study: NCT05676073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 dose 1
Description: Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 dose 2
Description: Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Study: NCT06377683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dansyl-PSMA radioligand therapy
Description: Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
Study: NCT05678153

Intervention type: DIAGNOSTIC_TEST
Intervention: Nordic Orofacial Test-Screen (NOT-S)
Description: screening tool to detect orofacial dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: Nordic Orofacial Test-Screen (NOT-S)
Description: screening tool to detect orofacial dysfunction
Study: NCT06526728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
Study: NCT03660072

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT05013723

Intervention type: OTHER
Intervention: Surveys
Description: Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)

Intervention type: OTHER
Intervention: Surveys
Description: Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
Study: NCT04327310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: humanized mAb against CD147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline (0.9%)
Description: Sterile normal saline (0.9%)
Study: NCT05280704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with lidocaine
Description: Dorsal digital block with lidocaine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with lidocaine
Description: Dorsal digital block with lidocaine
Study: NCT05572190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs
Study: NCT05895773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline spray
Description: Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
Study: NCT05572190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs
Study: NCT05280704

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with saline
Description: Dorsal digital block with saline

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dorsal digital block with saline
Description: Dorsal digital block with saline
Study: NCT05572190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs
Study: NCT05243056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive enhanced usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Y-AMBIENT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05572190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs
Study: NCT05319600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes behavior change skills training
Description: Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion program
Description: The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.
Study: NCT06193902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEU011
Description: Immunotherapy
Study: NCT05998408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
Study: NCT05243056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05572190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Description: Hydrocodone prodrugs
Study: NCT06046287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and hyaluronidase-fihj
Description: subucatneous, fixed dose 1800mg combination drug product containing rHuPH20 drug substance (2000 U/mL) and daratumumab drug substance (120 mg/mL) will be administered weekly for the first 8 weeks, and then every 2 weeks from week 9 to week 24.
Study: NCT06476808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986463
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986463
Description: Specified dose on specified days
Study: NCT06488547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DF)
Description: Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation.
Study: NCT05243056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06675682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
Description: Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
Study: NCT05998408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
Study: NCT06057948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-821 (QS-21)
Description: Comprised of the immunological adjuvant OPT-821 (QS-21)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-821 (QS-21)
Description: Comprised of the immunological adjuvant OPT-821 (QS-21)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral β-glucan
Description: Participants will be randomized to receive this agent in two different schedules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral β-glucan
Description: Participants will be randomized to receive this agent in two different schedules
Study: NCT06115668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive end-expiratory pressure 5 (PEEP 5)
Description: Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized positive end-expiratory pressure (PEEPIND)
Description: Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O